HealthCap

About HealthCap

HealthCap is one of Europe's longest-track-record dedicated life sciences venture capital firms with more than €1.2 billion of cumulative committed capital across 9 funds as of December 2024 (HealthCap IX closed April 2025 with €48 million anchor from Novo Holdings and EIFO), headquartered in Stockholm with an additional office in Lausanne. The firm was founded in 1996 and operates as a partner-owned independent VC. HealthCap has backed 132 portfolio companies historically with 34 plus approved drugs, 48 IPOs across 14 markets and over 5 million patients treated.

Investment thesis

HealthCap deploys capital through nine flagship funds (HealthCap I through IX), targeting multi-stage life sciences venture investments in targeted therapies for rare diseases, cancers and genetic disorders. The platform deploys across clinical and preclinical biotech. Sector focus spans biotechnology, pharmaceuticals, therapeutics, medical devices, precision medicine and diagnostics. Geographic deployment is anchored in the Nordics (Sweden, Denmark, Finland, Norway) with global syndicate co-investments across Europe and the US.

Recent activity

Recent realised exits include biotech (2025), therapeutics (2025), biotech (2024) and medical devices (2024). Recent acquisitions include Hemab Series C (biotech, October 2025), Step Pharma Series C (therapeutics, October 2025), Tribune Therapeutics (biotech, March 2025) and Positrigo (medical devices, June 2025). The platform continues active deployment of HealthCap IX across the Nordic life sciences ecosystem. Detailed buyer names and multiple data available on Pro at €49/month.